The U.S. Food and Drug Administration (FDA) has approved VIZZ (aceclidine ophthalmic solution 1.44%), a first-of-its-kind prescription eye drop designed to improve near vision in adults with age-related presbyopia. The decision, announced on July 31, 2025, marks a major milestone in vision care and offers a practical alternative to reading glasses, contact lenses, or surgery.
What Is Presbyopia?
Presbyopia is a common age-related condition that typically begins in the early 40s, when the eye’s lens loses elasticity and struggles to focus on close-up objects. Nearly 128 million Americans are affected, and until now, corrective lenses or surgical procedures were the primary solutions.
How VIZZ Works
The new drops use a technique called pupil-selective miosis. A single drop causes the pupil to constrict to less than two millimeters, creating a “pinhole effect” that sharpens near vision while maintaining distance clarity.
In Phase 3 clinical trials (CLARITY 1, 2, and 3), more than 70% of participants gained at least three lines of improvement on a standard near-vision chart within 30 minutes. For many, the benefits lasted up to 10 hours—enough to cover a workday or evening out.
Safety and Side Effects
VIZZ was well tolerated during more than 30,000 treatment days of testing. Reported side effects included:
- Mild eye irritation (20%)
- Dim vision in low-light conditions (16%)
- Headaches (13%)
These were typically mild and temporary. However, because pupil constriction may impair night vision, patients are advised to use caution when driving in the dark. Rare but serious risks include retinal tears or detachment. Physicians are recommended to conduct a retinal exam before prescribing and to educate patients on warning signs such as flashes of light or sudden floaters.
Availability Timeline
Developer Lenz Therapeutics expects to distribute samples to eye-care providers beginning October 2025, with a full commercial launch planned for late 2025. The drops will be available by prescription only.
How It Compares to Other Options
The FDA previously approved Vuity (pilocarpine hydrochloride 1.25%) in 2021, another eye drop for presbyopia. However, Vuity’s effects typically last about six hours and may blur distance vision. VIZZ promises longer-lasting results with fewer compromises, potentially making it a more convenient choice.
A Shift in Vision Care
Experts say VIZZ represents a new chapter in ocular pharmacology, offering a non-invasive daily option that takes effect in under 30 minutes. While it does not reverse aging of the eye, it could reduce dependence on reading glasses for millions of people.
Wider adoption will depend on long-term safety data, real-world performance, and insurance coverage. Still, ophthalmologists are calling this approval a breakthrough that could change how presbyopia is managed worldwide.
YOU MAY ALSO LIKE
Dry Eyes Is A Symptom Of What?
Anti-Aging Drugs Pose Serious Eye and Heart Risks for Women
Screens and Myopia: How Daily Device Use Could Harm Your Eyes
